Jubilant Pharmova Ltd saw its bottom line collapse in the second quarter. The drugmaker reported a 74.1% year-on-year plunge in consolidated net profit to ₹31.2 crore for the quarter ended September 30, down sharply from ₹120.3 crore in the year-ago period, according to its regulatory filing.
But top-line expansion offered no shelter. Revenue from operations climbed 20.5% to ₹2,370 crore compared with ₹1,966.4 crore a year earlier, yet surging operational friction dismantled operational leverage across primary business units. Operating profitability deteriorated rapidly—earnings before interest, tax, depreciation, and amortisation (EBITDA) dropped 29.3% to ₹241 crore from ₹341 crore. The operating EBITDA margin shrank by 720 basis points, retreating to 10.2% from 17.4% in the corresponding quarter last year.
The market reacted swiftly. Shares of Jubilant Pharmova ended Friday down ₹16.25, or 1.65%, at ₹965.90 on the BSE.
The sharpest blow landed inside the contract manufacturing pipeline. Contract Development and Manufacturing Organisation (CDMO) – Sterile Injectables booked a segment operating loss of ₹4.2 crore, crashing from an operating profit of ₹71 crore logged during the same period last year. Yet top-line billing across the division expanded, with segment revenue leaping to ₹559.6 crore from ₹411.5 crore—underscoring that heavier volumes failed to offset mounting cost pressures.
Core business lines experienced broad-based margin dilution before taxes, finance costs, and exceptional items:
Radiopharma: Segment earnings slumped to ₹69.8 crore from ₹95.5 crore, even as revenue advanced to ₹1,009.3 crore from ₹897.1 crore.
Allergy Immunotherapy: Operating profit fell to ₹65.7 crore against ₹74.9 crore a year prior, despite top-line sales advancing to ₹229.5 crore from ₹194 crore.
CRDMO: Contract Research, Development and Manufacturing Organisation earnings stood at ₹20 crore compared with ₹29 crore, while revenue rose to ₹344.8 crore against ₹312.5 crore.
Generics Turnaround: Generics provided a rare operational buffer, booking a segment profit of ₹5.1 crore against an operating loss of ₹3.1 crore last year, as revenue scaled to ₹274.1 crore from ₹167 crore.
The shift comes after the company's US CMO facility secured a 'Voluntary Action Indicated' (VAI) classification from regulatory authorities.
| Financial Metric | Q2 Current Period | Q2 Year-Ago Period | YoY Change (%) |
|---|---|---|---|
| Revenue from Operations | ₹2,370.0 Cr | ₹1,966.4 Cr | +20.5% |
| Consolidated Net Profit | ₹31.2 Cr | ₹120.3 Cr | -74.1% |
| Operating EBITDA | ₹241.0 Cr | ₹341.0 Cr | -29.3% |
| EBITDA Margin (%) |
The second-quarter erosion deepened damage across the company’s broader fiscal ledger. For the six months ended September 30, 2026, consolidated revenue from operations expanded to ₹4,599.4 crore compared with ₹3,867.1 crore in the first half of the preceding year.
Profit attributable to owners told a bleaker story. It cratered to ₹87.7 crore across the six-month stretch—down 60.7% from ₹223.2 crore generated in the corresponding half-year period.
Market Context: The divergence between 20.5% top-line revenue expansion and a 74.1% collapse in net profit highlights acute vulnerability inside high-complexity manufacturing assets, where operational interruptions and fixed overheads can rapidly wipe out cash margins despite robust delivery pipelines.
Leadership will confront market scrutiny immediately. Jubilant Pharmova management is scheduled to address institutional investors and financial analysts during an earnings webinar on Nov. 16, where executives will face granular queries on injectable plant profitability and margin recovery timelines.
| 10.2% |
| 17.4% |
| -720 bps |
| BSE Closing Share Price | ₹965.90 | — | -1.65% |